…injury leads to release of cardiac troponin, but troponin elevation is not specific for myocardial infarction. Other conditions may produce cardiomyocyte injury and elevated troponin…

…presentation and symptoms Clinical presentation is heterogeneous. Patients may have: Chest pain, pressure, tightness, heaviness, or discomfort. Pain radiating to the neck, jaw, shoulders, back…

…including carbamazepine, theophylline and quinine. Repeated dosing may also be appropriate after large ingestions of modified release preparations. Contraindications Measure Contraindication : : Medicinal charcoal A reduced…

…ingested substance has the propensity to form bezoars or is a sustained release formulation. Note: activated charcoal is ineffective against alcohols, lithium, and heavy metals…

…infarction (AMI), in which myocardial ischaemia is accompanied by cardiomyocyte necrosis and cardiac troponin release meeting the criteria of the universal definition of MI. Clinically…

…1. Perform an ABCDE assessment, attach cardiac monitoring, secure intravenous access and record an ECG. 2. Confirm the potassium with a repeat sample, but do…

…must be taken into account). Known allergy to the preparation — rare; itching and urticaria are usually due to histamine release, not allergy. Concurrent MAO inhibitor…

…with modified release preparations, mixed poisoning, pregnancy, children, a need for an antidote or dialysis, and whenever the clinical course deviates from what was expected…

…through intimal thickening. DES release antiproliferative and anti inflammatory agents from the stent surface and have substantially reduced this process compared with BMS. Neoatherosclerosis Neoatherosclerosis…

…They are released principally by ventricular cardiomyocytes in response to increased transmural stress and ventricular stretch. Atrial natriuretic peptide is produced predominantly by atrial tissue…